AstraZeneca (AZN) Share Price, News & Analysis

Company Overview

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.

Key Stats

• Today's Range: £123.96 to £125.96
• 50-Day Range: £114.60 to £131.34
• 52-Week Range: £107.84 to £157.32
• Volume: 7.17 million shs
• Average Volume: 31.35 million shs
• Market Capitalization: £193.86 billion
• P/E Ratio: 18.71
• Dividend Yield: 1.92%
• Price Target: £150
• Consensus Rating: Moderate Buy

AstraZeneca Stock Analysis - MarketRank™

AstraZeneca scored higher than 92% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.0 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

AstraZeneca has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on no strong buy ratings, 6 buy ratings, 1 hold rating, and no sell ratings.

Upside Potential

AstraZeneca has a consensus price target of £150, representing about 20.0% upside from its current price of £125.

Amount of Analyst Coverage

AstraZeneca has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of AstraZeneca is 18.71, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 42.04.

Price to Earnings Ratio vs. Sector

The P/E ratio of AstraZeneca is 18.71, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 210.29.

Price to Earnings Growth Ratio

AstraZeneca has a PEG Ratio of 0.86. PEG Ratios below 1 indicate that a company could be undervalued.

Price to Book Value per Share Ratio

AstraZeneca has a P/B Ratio of 4.75. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for AZN.

Dividend

• Score: 1.7 / 5
• Dividend Strength: Weak

Dividend Yield

AstraZeneca pays a meaningful dividend of 1.92%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

AstraZeneca does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of AstraZeneca is 47.41%. This payout ratio is at a healthy, sustainable level, below 75%.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: 0.33

News Sentiment

AstraZeneca has a news sentiment score of 0.33. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.56 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 16 news articles for AstraZeneca this week, compared to 4 articles on an average week.

Search Interest

Only 27 people have searched for AZN on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

2 people have added AstraZeneca to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 2.1 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, AstraZeneca insiders have bought more of their company's stock than they have sold. Specifically, they have bought £303,025 in company stock and sold GBX 0 in company stock.

Percentage Held by Insiders

0.15% of the stock of AstraZeneca is held by insiders.

Percentage Held by Institutions

67.75% of the stock of AstraZeneca is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: LON:AZN
• CIK: N/A
• Web: www.astrazeneca.com
• Phone: +44-20-73045000
• Fax: N/A
• Employees: 96,100
• Year Founded: N/A

Price Target and Rating

• Average Price Target for AstraZeneca: £150
• High Price Target: £178
• Low Price Target: £117
• Potential Upside/Downside: +20.0%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.86
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): GBX 668
• Trailing P/E Ratio: 18.71
• Forward P/E Ratio: 17.13
• P/E Growth: 0.86
• Net Income: £8.71 billion
• Net Margins: 17.02%
• Pretax Margin: N/A
• Return on Equity: 21.68%
• Return on Assets: 7.68%

Debt

• Debt-to-Equity Ratio: 64.10
• Current Ratio: 0.89
• Quick Ratio: 0.59

Sales & Book Value

• Annual Sales: £61.37 billion
• Price / Sales: 3.16
• Cash Flow: GBX 321.41 per share
• Price / Cash Flow: 38.89
• Book Value: GBX 2,630 per share
• Price / Book: 4.75

Miscellaneous

• Outstanding Shares: 1,550,896,000
• Free Float: N/A
• Market Cap: £193.86 billion
• Optionable: Not Optionable
• Beta: 0.21